Global Antibody Therapeutics- Market

Antibody Therapeutics- Comprehensive Study by Drug Type (Monoclonal antibodies, Polyclonal antibodies, Antibody-drug conjugates, Bispecific Antibody, Radio-immunotherapy, Antibody Fragment, Others), End User (Hospitals, Pharmaceuticals Companies, Government and Regulatory Agencies, Clinical Trial Participant, Others), Disease Indication (Asthma, Poisoning, Septicemia, Substance abuse, Viral infections, Cardiovascular Diseases, Cancer, Autoimmune Disorders, Others) Players and Region - Global Market Outlook to 2030

Antibody Therapeutics- Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 10.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled

Report Objectives / Segmentation Covered

By Drug Type
  • Monoclonal antibodies
  • Polyclonal antibodies
  • Antibody-drug conjugates
  • Bispecific Antibody
  • Radio-immunotherapy
  • Antibody Fragment
  • Others

By End User
  • Hospitals
  • Pharmaceuticals Companies
  • Government and Regulatory Agencies
  • Clinical Trial Participant
  • Others

By Disease Indication
  • Asthma
  • Poisoning
  • Septicemia
  • Substance abuse
  • Viral infections
  • Cardiovascular Diseases
  • Cancer
  • Autoimmune Disorders
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing a wide range of diseases, such as cancer, autoimmune disorders, and infectious diseases.
      • 3.2.2. There is a growing need for manufacturers capable of producing these complex biopharmaceuticals.
    • 3.3. Market Challenges
      • 3.3.1. Scaling up antibody production from laboratory-scale to commercial-scale manufacturing can be challenging.
    • 3.4. Market Trends
      • 3.4.1. Governments and regulatory agencies are providing support and incentives for the development and manufacturing of biopharmaceuticals
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antibody Therapeutics-, by Drug Type, End User, Disease Indication and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Antibody Therapeutics- (Value)
      • 5.2.1. Global Antibody Therapeutics- by: Drug Type (Value)
        • 5.2.1.1. Monoclonal antibodies
        • 5.2.1.2. Polyclonal antibodies
        • 5.2.1.3. Antibody-drug conjugates
        • 5.2.1.4. Bispecific Antibody
        • 5.2.1.5. Radio-immunotherapy
        • 5.2.1.6. Antibody Fragment
        • 5.2.1.7. Others
      • 5.2.2. Global Antibody Therapeutics- by: End User (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Pharmaceuticals Companies
        • 5.2.2.3. Government and Regulatory Agencies
        • 5.2.2.4. Clinical Trial Participant
        • 5.2.2.5. Others
      • 5.2.3. Global Antibody Therapeutics- by: Disease Indication (Value)
        • 5.2.3.1. Asthma
        • 5.2.3.2. Poisoning
        • 5.2.3.3. Septicemia
        • 5.2.3.4. Substance abuse
        • 5.2.3.5. Viral infections
        • 5.2.3.6. Cardiovascular Diseases
        • 5.2.3.7. Cancer
        • 5.2.3.8. Autoimmune Disorders
        • 5.2.3.9. Others
      • 5.2.4. Global Antibody Therapeutics- Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Antibody Therapeutics-: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. H. Lundbeck A/S (Denmark)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck KGaA (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bristol-Myers Squibb (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AbbVie Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Ultragenyx Pharmaceutical Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Antibody Therapeutics- Sale, by Drug Type, End User, Disease Indication and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Antibody Therapeutics- (Value)
      • 7.2.1. Global Antibody Therapeutics- by: Drug Type (Value)
        • 7.2.1.1. Monoclonal antibodies
        • 7.2.1.2. Polyclonal antibodies
        • 7.2.1.3. Antibody-drug conjugates
        • 7.2.1.4. Bispecific Antibody
        • 7.2.1.5. Radio-immunotherapy
        • 7.2.1.6. Antibody Fragment
        • 7.2.1.7. Others
      • 7.2.2. Global Antibody Therapeutics- by: End User (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Pharmaceuticals Companies
        • 7.2.2.3. Government and Regulatory Agencies
        • 7.2.2.4. Clinical Trial Participant
        • 7.2.2.5. Others
      • 7.2.3. Global Antibody Therapeutics- by: Disease Indication (Value)
        • 7.2.3.1. Asthma
        • 7.2.3.2. Poisoning
        • 7.2.3.3. Septicemia
        • 7.2.3.4. Substance abuse
        • 7.2.3.5. Viral infections
        • 7.2.3.6. Cardiovascular Diseases
        • 7.2.3.7. Cancer
        • 7.2.3.8. Autoimmune Disorders
        • 7.2.3.9. Others
      • 7.2.4. Global Antibody Therapeutics- Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antibody Therapeutics-: by Drug Type(USD Billion)
  • Table 2. Antibody Therapeutics- Monoclonal antibodies , by Region USD Billion (2018-2023)
  • Table 3. Antibody Therapeutics- Polyclonal antibodies , by Region USD Billion (2018-2023)
  • Table 4. Antibody Therapeutics- Antibody-drug conjugates , by Region USD Billion (2018-2023)
  • Table 5. Antibody Therapeutics- Bispecific Antibody , by Region USD Billion (2018-2023)
  • Table 6. Antibody Therapeutics- Radio-immunotherapy , by Region USD Billion (2018-2023)
  • Table 7. Antibody Therapeutics- Antibody Fragment , by Region USD Billion (2018-2023)
  • Table 8. Antibody Therapeutics- Others , by Region USD Billion (2018-2023)
  • Table 9. Antibody Therapeutics-: by End User(USD Billion)
  • Table 10. Antibody Therapeutics- Hospitals , by Region USD Billion (2018-2023)
  • Table 11. Antibody Therapeutics- Pharmaceuticals Companies , by Region USD Billion (2018-2023)
  • Table 12. Antibody Therapeutics- Government and Regulatory Agencies , by Region USD Billion (2018-2023)
  • Table 13. Antibody Therapeutics- Clinical Trial Participant , by Region USD Billion (2018-2023)
  • Table 14. Antibody Therapeutics- Others , by Region USD Billion (2018-2023)
  • Table 15. Antibody Therapeutics-: by Disease Indication(USD Billion)
  • Table 16. Antibody Therapeutics- Asthma , by Region USD Billion (2018-2023)
  • Table 17. Antibody Therapeutics- Poisoning , by Region USD Billion (2018-2023)
  • Table 18. Antibody Therapeutics- Septicemia , by Region USD Billion (2018-2023)
  • Table 19. Antibody Therapeutics- Substance abuse , by Region USD Billion (2018-2023)
  • Table 20. Antibody Therapeutics- Viral infections , by Region USD Billion (2018-2023)
  • Table 21. Antibody Therapeutics- Cardiovascular Diseases , by Region USD Billion (2018-2023)
  • Table 22. Antibody Therapeutics- Cancer , by Region USD Billion (2018-2023)
  • Table 23. Antibody Therapeutics- Autoimmune Disorders , by Region USD Billion (2018-2023)
  • Table 24. Antibody Therapeutics- Others , by Region USD Billion (2018-2023)
  • Table 25. South America Antibody Therapeutics-, by Country USD Billion (2018-2023)
  • Table 26. South America Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 27. South America Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 28. South America Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 29. Brazil Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 30. Brazil Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 31. Brazil Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 32. Argentina Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 33. Argentina Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 34. Argentina Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 35. Rest of South America Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 36. Rest of South America Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 37. Rest of South America Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 38. Asia Pacific Antibody Therapeutics-, by Country USD Billion (2018-2023)
  • Table 39. Asia Pacific Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 40. Asia Pacific Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 41. Asia Pacific Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 42. China Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 43. China Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 44. China Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 45. Japan Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 46. Japan Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 47. Japan Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 48. India Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 49. India Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 50. India Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 51. South Korea Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 52. South Korea Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 53. South Korea Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 54. Taiwan Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 55. Taiwan Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 56. Taiwan Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 57. Australia Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 58. Australia Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 59. Australia Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 60. Rest of Asia-Pacific Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 61. Rest of Asia-Pacific Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 62. Rest of Asia-Pacific Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 63. Europe Antibody Therapeutics-, by Country USD Billion (2018-2023)
  • Table 64. Europe Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 65. Europe Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 66. Europe Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 67. Germany Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 68. Germany Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 69. Germany Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 70. France Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 71. France Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 72. France Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 73. Italy Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 74. Italy Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 75. Italy Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 76. United Kingdom Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 77. United Kingdom Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 78. United Kingdom Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 79. Netherlands Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 80. Netherlands Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 81. Netherlands Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 82. Rest of Europe Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 83. Rest of Europe Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 84. Rest of Europe Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 85. MEA Antibody Therapeutics-, by Country USD Billion (2018-2023)
  • Table 86. MEA Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 87. MEA Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 88. MEA Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 89. Middle East Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 90. Middle East Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 91. Middle East Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 92. Africa Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 93. Africa Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 94. Africa Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 95. North America Antibody Therapeutics-, by Country USD Billion (2018-2023)
  • Table 96. North America Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 97. North America Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 98. North America Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 99. United States Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 100. United States Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 101. United States Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 102. Canada Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 103. Canada Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 104. Canada Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 105. Mexico Antibody Therapeutics-, by Drug Type USD Billion (2018-2023)
  • Table 106. Mexico Antibody Therapeutics-, by End User USD Billion (2018-2023)
  • Table 107. Mexico Antibody Therapeutics-, by Disease Indication USD Billion (2018-2023)
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Antibody Therapeutics-: by Drug Type(USD Billion)
  • Table 119. Antibody Therapeutics- Monoclonal antibodies , by Region USD Billion (2025-2030)
  • Table 120. Antibody Therapeutics- Polyclonal antibodies , by Region USD Billion (2025-2030)
  • Table 121. Antibody Therapeutics- Antibody-drug conjugates , by Region USD Billion (2025-2030)
  • Table 122. Antibody Therapeutics- Bispecific Antibody , by Region USD Billion (2025-2030)
  • Table 123. Antibody Therapeutics- Radio-immunotherapy , by Region USD Billion (2025-2030)
  • Table 124. Antibody Therapeutics- Antibody Fragment , by Region USD Billion (2025-2030)
  • Table 125. Antibody Therapeutics- Others , by Region USD Billion (2025-2030)
  • Table 126. Antibody Therapeutics-: by End User(USD Billion)
  • Table 127. Antibody Therapeutics- Hospitals , by Region USD Billion (2025-2030)
  • Table 128. Antibody Therapeutics- Pharmaceuticals Companies , by Region USD Billion (2025-2030)
  • Table 129. Antibody Therapeutics- Government and Regulatory Agencies , by Region USD Billion (2025-2030)
  • Table 130. Antibody Therapeutics- Clinical Trial Participant , by Region USD Billion (2025-2030)
  • Table 131. Antibody Therapeutics- Others , by Region USD Billion (2025-2030)
  • Table 132. Antibody Therapeutics-: by Disease Indication(USD Billion)
  • Table 133. Antibody Therapeutics- Asthma , by Region USD Billion (2025-2030)
  • Table 134. Antibody Therapeutics- Poisoning , by Region USD Billion (2025-2030)
  • Table 135. Antibody Therapeutics- Septicemia , by Region USD Billion (2025-2030)
  • Table 136. Antibody Therapeutics- Substance abuse , by Region USD Billion (2025-2030)
  • Table 137. Antibody Therapeutics- Viral infections , by Region USD Billion (2025-2030)
  • Table 138. Antibody Therapeutics- Cardiovascular Diseases , by Region USD Billion (2025-2030)
  • Table 139. Antibody Therapeutics- Cancer , by Region USD Billion (2025-2030)
  • Table 140. Antibody Therapeutics- Autoimmune Disorders , by Region USD Billion (2025-2030)
  • Table 141. Antibody Therapeutics- Others , by Region USD Billion (2025-2030)
  • Table 142. South America Antibody Therapeutics-, by Country USD Billion (2025-2030)
  • Table 143. South America Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 144. South America Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 145. South America Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 146. Brazil Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 147. Brazil Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 148. Brazil Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 149. Argentina Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 150. Argentina Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 151. Argentina Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 152. Rest of South America Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 153. Rest of South America Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 154. Rest of South America Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 155. Asia Pacific Antibody Therapeutics-, by Country USD Billion (2025-2030)
  • Table 156. Asia Pacific Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 157. Asia Pacific Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 158. Asia Pacific Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 159. China Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 160. China Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 161. China Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 162. Japan Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 163. Japan Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 164. Japan Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 165. India Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 166. India Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 167. India Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 168. South Korea Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 169. South Korea Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 170. South Korea Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 171. Taiwan Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 172. Taiwan Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 173. Taiwan Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 174. Australia Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 175. Australia Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 176. Australia Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 177. Rest of Asia-Pacific Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 178. Rest of Asia-Pacific Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 179. Rest of Asia-Pacific Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 180. Europe Antibody Therapeutics-, by Country USD Billion (2025-2030)
  • Table 181. Europe Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 182. Europe Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 183. Europe Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 184. Germany Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 185. Germany Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 186. Germany Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 187. France Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 188. France Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 189. France Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 190. Italy Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 191. Italy Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 192. Italy Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 193. United Kingdom Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 194. United Kingdom Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 195. United Kingdom Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 196. Netherlands Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 197. Netherlands Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 198. Netherlands Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 199. Rest of Europe Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 200. Rest of Europe Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 201. Rest of Europe Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 202. MEA Antibody Therapeutics-, by Country USD Billion (2025-2030)
  • Table 203. MEA Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 204. MEA Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 205. MEA Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 206. Middle East Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 207. Middle East Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 208. Middle East Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 209. Africa Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 210. Africa Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 211. Africa Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 212. North America Antibody Therapeutics-, by Country USD Billion (2025-2030)
  • Table 213. North America Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 214. North America Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 215. North America Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 216. United States Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 217. United States Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 218. United States Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 219. Canada Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 220. Canada Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 221. Canada Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 222. Mexico Antibody Therapeutics-, by Drug Type USD Billion (2025-2030)
  • Table 223. Mexico Antibody Therapeutics-, by End User USD Billion (2025-2030)
  • Table 224. Mexico Antibody Therapeutics-, by Disease Indication USD Billion (2025-2030)
  • Table 225. Research Programs/Design for This Report
  • Table 226. Key Data Information from Secondary Sources
  • Table 227. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antibody Therapeutics-: by Drug Type USD Billion (2018-2023)
  • Figure 5. Global Antibody Therapeutics-: by End User USD Billion (2018-2023)
  • Figure 6. Global Antibody Therapeutics-: by Disease Indication USD Billion (2018-2023)
  • Figure 7. South America Antibody Therapeutics- Share (%), by Country
  • Figure 8. Asia Pacific Antibody Therapeutics- Share (%), by Country
  • Figure 9. Europe Antibody Therapeutics- Share (%), by Country
  • Figure 10. MEA Antibody Therapeutics- Share (%), by Country
  • Figure 11. North America Antibody Therapeutics- Share (%), by Country
  • Figure 12. Global Antibody Therapeutics- share by Players 2023 (%)
  • Figure 13. Global Antibody Therapeutics- share by Players (Top 3) 2023(%)
  • Figure 14. Global Antibody Therapeutics- share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 18. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 19. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 20. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 22. H. Lundbeck A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 23. H. Lundbeck A/S (Denmark) Revenue: by Geography 2023
  • Figure 24. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 28. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 29. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 30. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 31. Sanofi (France) Revenue: by Geography 2023
  • Figure 32. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 34. Ultragenyx Pharmaceutical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Ultragenyx Pharmaceutical Inc. (United States) Revenue: by Geography 2023
  • Figure 36. Global Antibody Therapeutics-: by Drug Type USD Billion (2025-2030)
  • Figure 37. Global Antibody Therapeutics-: by End User USD Billion (2025-2030)
  • Figure 38. Global Antibody Therapeutics-: by Disease Indication USD Billion (2025-2030)
  • Figure 39. South America Antibody Therapeutics- Share (%), by Country
  • Figure 40. Asia Pacific Antibody Therapeutics- Share (%), by Country
  • Figure 41. Europe Antibody Therapeutics- Share (%), by Country
  • Figure 42. MEA Antibody Therapeutics- Share (%), by Country
  • Figure 43. North America Antibody Therapeutics- Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis AG (Switzerland)
  • Johnson & Johnson (United States)
  • Amgen Inc. (United States)
  • H. Lundbeck A/S (Denmark)
  • Pfizer Inc. (United States)
  • Merck KGaA (Germany)
  • Bristol-Myers Squibb (United States)
  • Sanofi (France)
  • AbbVie Inc. (United States)
  • Ultragenyx Pharmaceutical Inc. (United States)
Additional players considered in the study are as follows:
Hoffmann-La Roche Ltd (Switzerland) , ADC Therapeutics SA (Switzerland) , Aurobindo Pharma Ltd. (India) , Otsuka Holdings Co. Ltd. (Japan) , F. Hoffmann-La Roche Ltd (Switzerland)
Select User Access Type

Key Highlights of Report


Feb 2024 231 Pages 59 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antibody Therapeutics- Market Quantitative research analysis
Global Antibody Therapeutics- Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Antibody Therapeutics- Market Report?

Have a Query? Click Here

Other Related Reports

Diabetes Pen- Comprehensive Study by Type (Reusable Pens, Disposable Pens), Application (Type 1 Diabetes, Type 2 Diabetes), End Users (Hospitals, Clinics, Others), Distribution Channel (Hospital Phar...
$ 3800
Advanced Ophthalmology Technologies- Comprehensive Study by Type (Diagnostic (Optical Coherence Tomography Scanners, Ophthalmic Ultrasound Imaging Systems, Wavefront Aberrometers, Optical Biometry Sy...
$ 3800
Chitin, Chitosan and Derivatives Comprehensive Study by Type (Chitin, Chitosan, Glucosamine, Others), Application (Healthcare & Pharmaceuticals, Water Treatment, Agriculture, Food & Beverages, Others...
$ 3800
OTC Vitamins and Minerals Dietary Supplement- Comprehensive Study by Type (Multivitamins, Vitamin Supplements, Mineral Supplements, Others), Application (Pain Relief, Sexual Wellness, Energy and Weig...
$ 3800
Whey Protein- Comprehensive Study by Type (Isolates, Concentrates, Hydrolysates), Application (Sports Nutrition, Dietary Supplements, Infant Formula, Food & Beverages, Pharmaceutical, Animal Feed, Ot...
$ 3800
Zirconia Dental Material- Comprehensive Study by Type (Zirconia dental disc, Zirconia dental block, Others), Application (Dental crowns, Dental bridges, Dentures, Others), End Users (Hospitals, Denta...
$ 3800